Dual Inhibition of Ornithine Decarboxylase and A₁ Adenosine Receptor Efficiently Suppresses Breast Tumor Cells.

ABSTRACT: Personized treatment of breast cancer is still a challenge, and more treatment options for breast cancer are warranted. Combination therapies have been a highly appreciated strategy for breast cancer treatment in recent years, and the development of new combination therapies could improve patient outcomes. Adenosine and polyamines are both endogenous metabolites with indispensable biological functions. Adenosine binds with the A₁ adenosine receptor (A₁AR) to downregulate cAMP concentration, and both low cAMP content and high polyamine levels stimulate the growth and proliferation of cancer cells. In this work, we initially used a polyamine synthesis inhibitor, DFMO (α-difluoromethylornithine), and an A₁AR inhibitor, DPCPX (8-cyclopentyl-1,3-dipropylx

SUBMITTER: Ma H 

PROVIDER: S-EPMC7991832 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature